| 3i
plc 3i is a world leader in private equity and venture capital. We are active across all stages of funding. From early-stage venture capital to growth capital and buyouts, we invest in some of the most exciting and ambitious companies in the world. We are dedicated to value creation. Our purpose is to substantially increase the value of our portfolio companies and then to realise this value, both for ourselves and for our partners, through trade sales and stock market listings. Our track record demonstrates that we have consistently achieved this – even in the toughest of bear markets. 3i’s international human network is unique. Our team of nearly 300 investment professionals spans three continents, linking us to a wealth of corporate contacts and industry experts. This gives us both a local and global view of industry trends. The breadth of our network ensures that we are able to bring together the best team, with the right experience and relationships for each investment opportunity. It also means we have the scale, the agility and the talent needed to deliver even the most challenging deals. |
 |
| Alizyme Alizyme is a drug development company. It develops new products to treat diseases with high unmet medical need and substantial market opportunity. To date it has focused on obesity and related diseases, such as diabetes, and on gastrointestinal disorders including irritable bowel syndrome, inflammatory bowel disease and mucositis, a serious side effect of cancer therapy. Alizyme takes drug product candidates from an
early stage into clinical development with the objective of demonstrating
their efficacy in patients and providing a comprehensive data package
to support the further development and commercialisation of the
drug. Alizyme owns the intellectual property rights to all four
drug products currently in clinical trials and has an exclusive
worldwide licence to the COLAL™ drug delivery system. |
 |
| AstraZeneca AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $18 billion. AstraZeneca provides new, effective medicines designed to fight disease in areas of high medical need including cancer, cardiovascular, CNS, GI, infection, pain control and respiratory. It has a powerful product portfolio with many world leading products in their sectors. AstraZeneca has active worldwide sales in over 100 countries and manufacturing in 20 with in total around 58,000 employees worldwide. AstraZeneca has an annual R & D spend of over $3 billion and employs over 10,000 people in R & D with major centres in 5 countries. It has a strong R & D pipeline with a number of significant innovations. AstraZeneca is committed to continued innovation including a focus on partnering, close customer relations, people development and a responsible approach to business. |
 |
| Atlas
Venture Atlas Venture is the leading international early-stage venture capital firm, investing in communications, information technology and life sciences companies. With investing offices in Boston, London, Munich and Paris, Atlas Venture divides its investments between the United States and Europe. Founded in 1980, Atlas Venture has organized six international funds, and currently manages $2.1 billion in committed capital. The Atlas Venture investment team is comprised of seasoned operating executives and career venture capitalists who have been deeply involved in the formation and development of more than 300 companies worldwide. For more information about Atlas Venture, go to www.atlasventure.com. |
 |
| Boehringer
Ingelheim Since 1885, Boehringer Ingelheim has been a family-owned company, headquartered in Ingelheim, Germany, with a long history of successfully marketed pharmaceutical innovations. The Boehringer Ingelheim group of companies ranks among the 20 leading pharmaceutical corporations in the world and has 152 subsidiaries in 45 countries worldwide. Focussing on human pharmaceuticals and animal health, it posted net sales of 7.4 billion EURO in 2003. The human pharmaceutical business, which accounts for 96% of sales, is comprised of prescription medicines, consumer health care products, chemicals and biopharmaceuticals for industrial customers. Research and development, production and distribution facilities are located around the globe. In 2003, Boehringer Ingelheim’s R&D spending was approx. 1.2 billion EURO which is more than one fifth of net sales in its largest business segment Prescription Medicines. We are actively seeking for in-licensing opportunities based on innovation and therapeutic progress. The primary focus is on indication areas where the Boehringer Ingelheim group of companies has proven expertise and a track record in development, registration and marketing, as well as in-house research programmes with potential for partnering opportunities in the areas of Respiratory, Cardiovascular, Metabolism, Virology, Central Nervous System/Neurology, Urology, Immunology, Oncology. |
 |
| Coller
Capital London-based Coller Capital, founded in 1990, is the leading global investor in private equity ‘secondaries’ – the purchase of original investors’ stakes in private equity funds (venture capital, buyout and mezzanine) or the acquisition of portfolios of companies from corporate owners/backers. Coller Capital’s current fund has commitments of $2.6 billion from 150 international institutional investors and is the largest secondaries fund in the world. The fund will invest from $1 million to more than $1 billion in a single transaction. The firm currently has 173 positions in 140 funds, through which it owns interests in more than 2000 companies worldwide. Coller Capital’s name is synonymous with the development of the secondaries marketplace. In 1994, the firm launched Europe’s first secondaries fund, and in 1998 the first global secondaries fund. In 1998, Coller Capital made the largest secondaries purchase of the time: the US-based Shell Pension Trust’s $265 million private equity portfolio. Two years later, the firm repeated the feat with the $1 billion purchase of National Westminster Bank’s private equity portfolio from NatWest’s acquirer, the Royal Bank of Scotland. In December 2001, the firm made the first significant purchase of a US corporate venture portfolio, acquiring 27 technology companies from Lucent’s Bell Labs, and in 2003 it created a joint venture with British Telecom’s corporate incubator, Brightstar. In February 2003, Coller Capital participated in the acquisition of Deutsche Bank’s €1.5 billion private equity portfolio – once again the largest-ever secondaries transaction, and in January 2004 the firm agreed to buy Abbey National’s $1.33 billion portfolio – the largest secondaries purchase by a single buyer. For more information about Coller Capital, visit its web site at www.collercapital.com |
 |
| Cyclacel Cyclacel Ltd is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. The company’s core areas of expertise are in cell cycle biology and the use of biomarkers in clinical trials. Cyclacel’s current pipeline comprises nine novel drug series: seven for cancer, one for HIV/AIDS and one for Type 2 Diabetes. Cyclacel’s lead drug candidate, CYC202, is the leading, orally available, CDK inhibitor currently in multi-centre Phase IIa clinical trials for hematological and lung cancers. Cyclacel’s second drug candidate, CYC682, is an orally available nucleoside analogue in Phase Ib clinical trials for the treatment of patients with advanced cancers. |
 |
| DyoDelta
Biosciences DyoDelta Biosciences specialises in partnerships in the Pharma / Biotech sector. It provides best-practice in corporate partnering through its management and associates. DyoDelta Biosciences’ concept is unique in terms of being not a consultancy but utilizing a group of senior executives with actual deal-making experience in the pharma and biotech industry at the corporate level, to instigate collaborations on behalf of its clients/partners. DyoDelta Biosciences covers Europe, the US and Japan, in guiding and supporting investors, pharma and biotech companies in corporate deals, covering all aspects of transactions in an integrated way including pre-qualifying identifying suitable opportunities, market projections, commercial evaluation and technical due diligence, deal structure, generating optimal financial terms, negotiations and contract drafting and post-deal management. In addition, DyoDelta Biosciences has two other distinct activities: 1) acting as a bio-incubator, licensing early-stage promising projects from academia with the potential to lead to novel pharmaceutical compounds and 2) introducing new pharmaceutical products through its network of collaborators and licensees in Europe and Asia. |
 |
| Greater
Zurich Area AG Greater Zurich Area AG as a marketing organization facilitates the market entry for foreign companies in Switzerland and supports them in their process to set up their local company as well as to establish their network in the Zurich Life sciences community. Zurich MedNet is the locally and internationally integrated life science cluster in the Greater Zurich Area. It includes more than 430 medical and biotech companies, universities, technical collages and technology transfer institutions. The Greater Zurich Area features numerous diversified research parks, business parks and several incubators to support a prosperous development of biotechnology companies. |
 |
| HBM
BioVentures Ltd HBM BioVentures Ltd is a holding company established under Swiss law, domiciled in Baar, Switzerland. The company invests primarily in later-stage private equity, but also in publicly traded small cap companies in the biotechnology, emerging pharmaceutical, medical technology and related industries, located mainly in Western Europe and the U.S. While most investments are made in companies directly, some take place through specialised, regional early-stage investment vehicles. HBM BioVentures offers institutional and private investors an ideal opportunity to invest in a broadly diversified portfolio combining private and public small cap companies to which they normally have limited access. HBM BioVentures is independent and offers a flexible investment vehicle as a platform for active financial engineering. It is managed by investment professionals and combines high transparency with an advantageous tax structure. |
 |
| Laboratories
Fournier S.A. Fournier Pharma is a key European-based company,
operating worldwide, dedicated to improve healthcare and quality
of life through innovative healthcare products and services for
the prevention and treatment of human diseases. In the last 15 years, Fournier Pharma has pushed ahead with its international development. Today, Fournier Phama has 70% of its turnover coming from outside of France and is further pursuing its development with the opening of several wholly owned affiliates including Australia. Fournier Pharma has established affiliates and representative offices in 30 countries including Europe, North America and Asia. Fournier Pharma holds key positions in the cardiovascular/metabolism fields and is recognized as an industry leader in this area, mainly through its core fenofibrate product (Lipanthyl, Lipidil) marketed in more than 80 countries. Fournier Pharma has signed key agreements for various leading products in CV diseases. Other fields of activities cover gynaecology, urology, antibiotics and CNS. Fournier Pharma's R&D division (72 Million
Euros spending in 2003) is organised around lifecycle management
and NCEs discovery in various fields: PARTNERING OBJECTIVES ALLIANCES |
 |
| Merck Merck is a global pharmaceutical and chemical company with sales of EUR 7.2 billion in 2003, a history that began in 1668, and a future shaped by 28,300 employees in 56 countries. Its success is characterized by innovations from entrepreneurial employees. Merck’s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds a 74% interest and free shareholders own the remaining 26%. The former U.S. subsidiary, Merck & Co., has been completely independent of the Merck Group since 1917. Merck Pharma Ethicals strategy is focused on oncology and cardio-metabolic care. Merck launched its first cancer treatment, Erbitux®, in Europe in 2003. |
 |
| Novartis
Pharma Profile to follow shortly. |
| Perseus-Soros
BioPharmaceutical Fund, LP The Perseus-Soros BioPharmaceutical Fund (PSBF) is a leading private equity fund that invests in life science companies developing biopharmaceutical products and creating businesses based on advanced life science technologies. Our primary investment interest is in later-stage product companies with minimal technological risk. PSBF is led by of a group of investment professionals with diverse backgrounds in industry, science, and finance. The team’s complementary backgrounds give PSBF unique perspective on the key players, events, and forces shaping the life science industry, and allow the Fund to identify superior investment opportunities. In working with our portfolio companies the principals of PSBF seek to provide the financing, relationships, and guidance needed to build highly successful companies. |
| Pictet
& Cie Founded in 1805 in Geneva, Pictet & Cie is today, with over CHF 183 bn under custody and administration, one of Switzerland's leading private bankers and one of the premier asset management specialists in Europe. Focused on asset management, the Pictet Group provides discerning private clients and leading institutions from around the world with a wide range of services: private banking, institutional asset management, fund administration and management, Swiss brokerage services, Global Custody and Family Office services. Organised as a partnership, Pictet & Cie belongs to and is run by nine partner-managers with joint and unlimited responsibility for the Bank's liabilities. Its exceptional solidity is acknowledged by two leading rating agencies who have awarded the Bank the highest possible rating. The Pictet group employs some 1,900 people, including over 460 investment professionals. As an international investor from the very early years, the Group has established offices in financial centres of strategic importance world-wide: Zurich, Lausanne, Frankfurt, Luxembourg, Paris, London, Milan, Florence, Turin, Nassau, Montreal, Rio de Janeiro, Singapore, Hong Kong and Tokyo. Pictet invests for its clients in over 80 countries. |
 |
| Roche Roche, based in Switzerland, is a leading healthcare company with a uniquely broad spectrum of innovative solutions. For more than 100 years, we have been active in the discovery, development, manufacture and marketing of novel healthcare solutions. Our products and services address prevention, diagnosis and treatment of diseases, thus enhancing well-being and quality of life. Arranged in two operative divisions, pharmaceuticals and diagnostics, our global mission today and tomorrow is to add exceptional value to healthcare. Roche employs more than 65,000 people and is present
in over 150 countries worldwide. This multinational presence reinforces
our ability to anticipate needs and to offer healthcare solutions
in all regions of the world. The Group has research and development
alliances with many partners, including majority ownership interests
in Genentech and Chugai. |
 |
| Serono
International Serono is a global biotechnology leader with over 4,600 employees, worldwide revenues of USD 2.019 billion and a net income of USD 390 million in the year 2003. The Company operates in 44 countries, with production facilities in eight countries and sales in 94 countries. Within its marketed franchises, Serono has products available in three core therapeutic areas: reproductive health, neurology, and growth and metabolism. It has six recombinant products on the market and a strong pipeline with over 30 ongoing development projects, based both on proteins and small molecules, focusing on the existing therapeutic areas as well as new targets such as dermatology, gastroenterology, oncology and autoimmune diseases. |
 |
| Sofinnova The Company Founded in Paris in 1972, Sofinnova Partners has €500 million of active funds under management. For 30 years we have played a major role as lead or co-lead investor in ambitious projects in information technologies and life sciences, in France and throughout Europe. We look for early-stage companies with high growth potential and strong management, in which we invest a minimum of €0.5 million and up to €15 million in several stages. We are a hands-on investment firm committed to creating successful independent businesses. Our investment professionals are all recognized experts in their field who bring valuable market and technical knowledge to our portfolio companies by taking active part on the board of directors. Sofinnova Partners is an independent partnership with strong ties to its US sister company, Sofinnova Ventures, based in San Francisco. Life sciences sector International Corporate
Office : |
 |
| Warburg
Pincus International LLC Warburg Pincus has been a leading private equity investor since 1971. The firm currently has approximately $14 billion under management, including $4 billion available for investment in a range of industries including business services, energy, financial services and technologies, healthcare and life sciences, information and communication technology, media and real estate. Warburg Pincus is an experienced partner to entrepreneurs seeking to create and build durable companies with sustainable value. The firm has an active portfolio of about 125 companies. Throughout its 35-year history in private equity, Warburg Pincus has invested at all stages of a company's life cycle, from founding start-ups and providing growth capital to leading restructurings, recapitalizations and buy-outs. The firm's tradition of successful investment activity, led by the same senior management group, has produced consistent top quartile returns. Since 1971, Warburg Pincus has sponsored ten private equity investment funds with committed capital in excess of $19 billion. These funds have invested more than $17 billion in approximately 480 companies in 30 countries. The principal investors in the funds managed by Warburg Pincus are public and private pension funds, institutional investors, foundations and endowment funds in the U.S. and abroad. In April 2002, Warburg Pincus closed its most recent global fund, Warburg Pincus Private Equity VIII, L.P., a $5.3 billion fund that invests in companies in the U.S. and abroad. Warburg Pincus, which was founded in 1966, has 54 partners and 111 professionals in offices in New York, Menlo Park, London, Munich, Hong Kong, Beijing, Singapore, Seoul, Tokyo and Mumbai. |
 |
| Wilshire
Associates Europe The Wilshire Private Markets Group (“WPMG”) is an institutional manager of private equity partnerships. Formed in 1984, the the group manages over $2.0 billion in private equity partnership investments for institutional investors. The WPMG has 28 professionals with offices in the U.S., Europe, and Asia/Australia. The WPMG invests in buyouts, venture capital, and secondaries on a global basis. Both global and regional mandates are structured to meet client investment objectives. |